Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int‐1‐risk MDS patients: Results of the phase II KALLISTO trial

Abstract

In this small pilot study, combining low-dose deferasirox with erythropoietin did not improve erythroid response. It remains of interest to investigate early chelation approaches with even lower deferasirox doses plus erythropoietin in lower-risk MDS patients before the onset of transfusion dependence.